Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
BERLIN:NVV1
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.37Last Year’s EPS
-0.44Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.Company Guidance
Significant Cost Reduction
Novavax reduced more than $1 billion in current liabilities by year-end 2024 compared to 2022 and decreased operating expenses by almost $1 billion in the same period.
Sanofi Partnership Expansion
The partnership with Sanofi includes the use of Novavax's Matrix-M adjuvant in Sanofi's pandemic flu vaccine candidate, securing $225 million in 2025 from achieved milestones.
Matrix-M Vaccine Advances
Novavax's Matrix-M adjuvant is crucial in the R21 malaria vaccine distributed in Africa, with approximately 25 million doses delivered to 24 countries.
Financial Improvements
Novavax brought in $60 million in near-term cash and anticipates long-term savings of approximately $230 million by consolidating its Maryland campus footprint.
Positive Revenue Framework Update
Novavax raised its 2025 revenue framework by $25 million at the midpoint, expecting adjusted total revenue between $1.040 billion and $1.060 billion.
DE:NVV1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:NVV1 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | €6.47 | €6.70 | +3.40% |
Aug 06, 2025 | €5.81 | €6.76 | +16.41% |
May 08, 2025 | €5.37 | €5.25 | -2.11% |
Feb 27, 2025 | €6.82 | €7.01 | +2.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novavax (DE:NVV1) report earnings?
Novavax (DE:NVV1) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Novavax (DE:NVV1) earnings time?
Novavax (DE:NVV1) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novavax stock?
The P/E ratio of Novavax is N/A.
What is DE:NVV1 EPS forecast?
DE:NVV1 EPS forecast for the fiscal quarter 2025 (Q4) is -0.37.
